symbol,name,description,country,year,period,documentUrl,income,expenses,postedName,date,clientId,registrantId,senateId,houseRegistrantId
SUPN,SUPERNUS PHARMACEUTICALS INC,Experience in developing and commercializing products that treat central nervous system,US,2022,Q3,https://lda.senate.gov/filings/public/filing/0ea41774-008f-417b-88ac-15c04071ad23/print/,20000,,,,52396,46038,46038-52396,34381
SUPN,SUPERNUS PHARMACEUTICALS INC,Experience in developing and commercializing products that treat central nervous system,US,2022,Q4,https://lda.senate.gov/filings/public/filing/d2432496-fa00-4530-8e82-2ba1f3fb4eb8/print/,20000,,,,52396,46038,46038-52396,34381
